ABCG2 p.Cys55Ala
[switch to full view]Comments [show]
None has been submitted yet.
PMID: 17159598
[PubMed]
Deeken JF et al: "Toward individualized treatment: prediction of anticancer drug disposition and toxicity with pharmacogenetics."
No.
Sentence
Comment
178
Table 5 Ethnic frequency (%) of allelic variants in CYP2C9 Allelic variant SNPs Caucasians African-Americans Asians Hispanics Africans CYP2C9*2 C430T 6.8-13.2 1.0-2.5 0 8.0 CYP2C9*3 A1075C 4.3-15.9 0.5-1.25 0-2.2 6.0 CYP2C9*5 C1080G 0 1.7 CYP2C9*7 C55A 7.1 CYP2C9*8 G449A 6.7 7.1 CYP2C9*9 A752G 0.5 13.3 14.3 CYP2C9*11 C1003T 1 CYP2C9*12 C1465T 0.5 SNP, single nucleotide polymorphism. Sources: Caucasians [51-54], African Americans [52,54,55], Asians [52,56], Hispanics [57], Africans [52].
X
ABCG2 p.Cys55Ala 17159598:178:248
status: NEW
PMID: 18430864
[PubMed]
Liu Y et al: "Effect of cysteine mutagenesis on the function and disulfide bond formation of human ABCG2."
No.
Sentence
Comment
111
Mutation of one or two of these residues (I2-CL, C284A, and C374A) did not signifi- TABLE 1 Primers used for construction of cysless mutants Mutations Primer Sequence RESa C43A TTTCATAACATTGCCTATCGAGTAAAACTGAAG BsrDI C55A GCTTTCTACCTGCACGAAAACCAGTTGAG BsgI C119A GCCAATTTCAAAGCGAATTCAGGTTACGTGG EcoRI C284A GAATCAGCTGGATATCACGCTGAGGCCTATAATAAC EcoRV C374A ACACCACCTCCTTCGCTCATCAACTCAGATG None C438A CTGACGACCAACCAAGCTTTCAGCAGTGTTTC HindIII C491A TATATTTACCGCTATAGTATACTTCATGTTAGG AccI C544A CTTCTCATGACGATCGCTTTTGTGTTTATGATG PvuI C592A GGACAAAACTTCGCCCCGGGACTCAATGCAA SmaI C603A/C608A AGGAAACAATCCTGCTAACTATGCAACAGCTACTGGCGAAGAATATTT -NspI C635A CACGTGGCCTTGGCTGCAATGATTGTTATTTTC BsrDI a Restriction (RES) enzyme digestion sites engineered in the primer for the convenience of detection.
X
ABCG2 p.Cys55Ala 18430864:111:217
status: VERIFIED